<DOC>
	<DOCNO>NCT02581878</DOCNO>
	<brief_summary>To establish recommend dose BAY1862864 Injection investigate study drug act body , cancer cell safe patient advance non-Hodgkin 's lymphoma ( NHL )</brief_summary>
	<brief_title>Safety Tolerability BAY1862864 Injection Subjects With Relapsed Refractory CD22-positive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The study divide two part : `` dose-escalation part '' evaluate safety profile explore Maximum tolerate dose ( MTD ) `` expansion part '' evaluate safety tumor response profile BAY1862864 Injection select dose .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Subject relapse refractory CD22positive histologically confirm NHL An archival paraffinembedded tissue fresh biopsy available retrospective quantitative assessment CD22 level Bone marrow involvement cellular marrow lymphoma determine &lt; 25 % Subject fail least one prior chemo/immunotherapybased regimen Life expectancy least 12 week Not eligible , refuse , fail highdose therapy combine autologous stem cell rescue ( HDT ASCR ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Women childbearing potential must negative pregnancy test within seven day start treatment Subject use adequate barrier birth control measure study willing continue use entire course study twelve month last administration BAY1862864 Injection Adequate bonemarrow , hepatic renal function Subject capable give informed consent provide consent write Previous exposure study drug . Previous exposure CD22 antibody within six month screen . Any radioimmunotherapy within six month screen . History anaphylactic reaction monoclonal antibody therapy . Known suspected allergy intolerance agent give course study . Anticancer immunotherapy and/or anti cancer chemotherapy within four week first dose study drug Previous therapy fludarabinecontaining regimen within three month screen Participation clinical trial subject receive active therapy within four week first schedule dose study drug Any toxic effect ( CTCAE ≥ Grade 2 ) previous anti cancer therapy ( incl . radiotherapy ) yet stabilize significant posttreatment toxicity observe Prior definitive radiotherapy complete less four week date schedule first dose BAY1862864 History symptomatic metastatic brain meningeal tumor . Presence new progressive brain metastasis . History clinically significant cardiac disease Clinically relevant finding ECG . Uncontrolled hypertension , define systolic blood pressure &gt; 160 mmHg / diastolic blood pressure &gt; 100 mmHg , despite optimum medical management History arterial venous thrombotic embolic event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , clinically relevant pulmonary embolism within three month first administration BAY1862864 Autologous bonemarrow transplant stemcell rescue within three month first administration BAY1862864 Organ allograft ( except corneal transplant ) allogeneic bonemarrow transplant time first administration BAY1862864 Positive result hepatitis virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) and/or human immunodeficiency virus antibody ( HIVAb ) test Significant liver dysfunction , define ChildPugh class B C Any active infection CTCAE Grade ≥2 Previous concurrent cancer distinct primary site histology cancer evaluate study Major surgery significant trauma within four week first administration BAY1862864 Any treatment biological response modifier ( , limit , granulocyte colonystimulating factor , G CSF ) , blood transfusion , within three week first administration BAY1862864 Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Current pregnancy breastfeed Any condition unstable could jeopardize safety subject his/her compliance study requirement Close affiliation investigation site Any use subject illicit drug substance may , opinion investigator his/her designate associate ( ) , reasonable chance contribute toxicity otherwise confound result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Thorium-227</keyword>
	<keyword>BAY1862864 Injection</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>CD22</keyword>
	<keyword>Radioimmunotherapy</keyword>
</DOC>